According to Turkish media reports, Turkey began final Phase III trials of an experimental Chinese coronavirus vaccine on 16 September 2020, Reuters news agency reported on Wednesday.
This vaccine will be administered to 1,200 to 1,300 health workers over 10 days and a second dose will be given 14 days after the first, broadcasters CNN Turk and Haberturk reported, with the results of the trial sent the World Health Organisation (WHO).
The broadcasters added that the vaccine candidate will later be administered to volunteers with chronic diseases, with the aim of vaccinating 13,000 people.
According to Reuters, Turkey's health ministry did not comment on the reports, however, Health Minister Fahrettin Koca is due to hold a news conference later on 16 September.
Koca had announced that Phase III work had started on the Chinese vaccine candidate, as well as another developed by Pfizer. Russia's application to conduct Phase III trials in Turkey for its experimental vaccine was being evaluated and a decision would likely be made this week, he had said.
China launched a vaccine emergency use programme in July 2020, offering three experimental shots developed by a unit of state pharmaceutical giant China National Pharmaceutical Group (Sinopharm) and US-listed Sinovac Biotech. A fourth COVID-19 vaccine being developed by CanSino Biologics was approved for use by the Chinese military in June.
Broadcaster Haberturk added that the vaccine candidate on trial in Turkey was developed by Sinovac.
Philips-led EXIT-CVD consortium launches cardiovascular clinical studies across Europe
SciBase technology selected as primary endpoint in NIH-led skin exposure study
Genezen agrees manufacturing collaboration with Galibra Neuroscience
Viking Therapeutics launches Phase 3 clinical programme for oral VK2735 in obesity
Coya Therapeutics plans open-label extension of COYA 302 ALS trial
Takeda reports positive Phase 2/3 results for investigational immunodeficiency therapy
Galderma to acquire ZO Skin Health for USD1.5bn to expand skincare portfolio
Orexo reports encouraging initial bioavailability results for oral semaglutide formulation
Pharming reports positive Phase II results for leniolisib in genetic immune disorders
Telix to present 20 abstracts on cancer theranostics at EANM Congress
CelLBxHealth secures USD65,000 pharmaceutical research contract
FDA grants Breakthrough Therapy Designation to Legacy Healthcare's CINAINU (LH-8)
Racura Oncology receives approval for RC220 trial to proceed to higher dose